Astrana Health, Inc. reported adjusted earnings of $2.18 per share for Q4 2025, surpassing analysts’ estimates by $0.19. Revenue reached $1.42 billion, a 12% year-over-year increase, driven by expanded outpatient services and rising demand for chronic disease management solutions.
- Adjusted EPS of $2.18 in Q4 2025, exceeding estimates by $0.19
- Revenue reached $1.42 billion, up 12% YoY
- 22% year-over-year increase in patient enrollment for chronic disease programs
- Digital health platform reduced readmission rates by 9%
- 2026 revenue guidance raised to $5.85B–$5.95B
- Stock surged 6.3% post-earnings, boosting XLV, AMGN, and JNJ
Astrana Health, Inc. delivered a standout performance in its fourth quarter of 2025, reporting adjusted earnings per share of $2.18, significantly exceeding the consensus forecast of $1.99. The company's total revenue climbed to $1.42 billion, marking a 12% increase compared to the same quarter in 2024, fueled by a 17% growth in outpatient care volume and expanded contracts with regional health systems. The results reflect stronger-than-expected demand across its core therapeutic areas, particularly in diabetes and cardiovascular care, where patient enrollment rose by 22% year-over-year. Astrana also announced the successful rollout of its digital health platform, which contributed to a 9% reduction in patient readmission rates, enhancing operational efficiency and improving care outcomes. In response to the strong quarter, the company raised its full-year 2026 guidance, projecting revenue between $5.85 billion and $5.95 billion, up from the prior range of $5.6 billion to $5.75 billion. The revised outlook signals confidence in its integrated care model and increasing market penetration, particularly in underserved urban and rural communities. The positive earnings report contributed to a 6.3% jump in Astrana’s stock price following the call, outperforming broader healthcare benchmarks. The move also lifted related equities, with Amgen (AMGN) gaining 2.1% and Johnson & Johnson (JNJ) rising 1.6%, while the Health Care Select Sector ETF (XLV) posted a 1.9% gain, indicating broad-based sector strength driven by improved visibility into healthcare delivery and biotech innovation.